EPISODE · Apr 24, 2026 · 1 MIN
Compass Pathways: Psychedelics Pioneer
from The Daily News Now! Business
President Trumps executive order expedites psychedelic therapies FDA approvals, boosting Compass Pathways (CMPS) stock. CMPS leads with COMP three sixty, a synthetic psilocybin for depression, boasting positive phase three data and a strong cash position, positioning them as the psychedelics frontrunner. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/71f9ee006a6e526a
NOW PLAYING
Compass Pathways: Psychedelics Pioneer
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m